Background: Liver biopsy is used as a golden standard for determining liver fibrosis stage. However, bleeding and sampling error may occur in liver biopsy because of the small sample size. Recently, elastography, particularly using FibroScan, as well as serum samples, have been reported to be useful for measuring liver stiffness.
Objective: Sixty-one patients with hepatitis C viruspositive chronic hepatitis or cirrhosis treated with direct acting agents (DAAs) were included in this study.
Methods: Results of liver elastography using FibroScan were compared with those of serum Mac-2 binding protein glycosylation isomer (M2BPGi), platelet count, FIB-4 index, and alpha-fetoprotein in each patient before and after treatment with DAA.
Results: Liver elastography using FibroScan was comparable to serum M2BPGi, platelet count, FIB-4 index, and alpha-fetoprotein. Serum M2BPGi, FIB-4 index, and alpha-fetoprotein values decreased in 2 weeks after DAA therapy initiation, while scores of liver elastography using FibroScan decreased in 12 weeks after DAA therapy initiation.
Conclusion: Liver elastography using FibroScan seemed to predict liver stiffness; however, serum M2BPGi, FIB-4 index, and alpha-fetoprotein values seemed to predict liver infection.
View full abstract